期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 24, 期 1, 页码 49-57出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2011.01.002
关键词
mesenchymal stem cells; autoimmune diseases; inflammation; cell therapy
类别
资金
- Medical Research Council [MC_G0802523] Funding Source: researchfish
- MRC [MC_G0802523] Funding Source: UKRI
- Medical Research Council [MC_G0802523] Funding Source: Medline
Mesenchymal stem cell (MSC) immunosuppressive properties offer a potentially attractive therapeutic modality for autoimmune diseases. MSC inhibit virtually all types of immune responses in vitro and prevent the induction of disease in several experimental models of autoimmunity. However, the processes involved in the pathogenesis of human diseases are more complicated and treatment cannot be administered before disease induction. In autoimmune diseases persistent antigenic stimulation recruits endogenous MSC to the site of lesion that contribute to the fibrotic evolution. Therefore, administering MSC to a chronic inflammatory disorder may not be desirable. In fact. MSC are not constitutively immunosuppressive but require a 'licensing' step provided by molecules of acute phase inflammation, like IFN gamma and TNF-alpha, or toll-like receptor (TLR) ligands. Conversely, different cytokines and/or the stimulation of selective TLR make MSC to become immunostimulatory. Therefore, dissecting the inflammatory environment in autoimmune diseases will identify the best conditions amenable to successful MSC therapy. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据